Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375193 · ClinicalTrials.gov registry record · Phase 2
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00375193 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 75 participants.
The verdict
NCT00375193, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.
Interventions
- DRUG Amrubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-11-01 |
| Est. Completion | 2009-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00375193
The ClinicalTrials.gov registry entry for NCT00375193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amrubicin is the first listed.
NCT00375193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00375193 about?
NCT00375193 is a clinical study titled "Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy". The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.
What is the current status of trial NCT00375193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2006-11-01. Estimated completion is 2009-03-01.
What interventions are being tested in trial NCT00375193?
The interventions under investigation include: Amrubicin (DRUG).
Who is sponsoring clinical trial NCT00375193?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.